Navigation Links
Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference

NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the official program of TAT: Target Alpha Therapy (TAT) international symposium will feature a presentation devoted to Actinium Pharmaceuticals' clinical programs.  The abstract entitled "Alpha-Particle Immunotherapy for Acute Myeloid Leukemia with Bismuth-213 and Actinium-225" has been accepted for oral presentation to be delivered by Dr. Joseph Jurcic , Chief of Leukemia Services at New York Presbyterian/Columbia.

"Alpha emitters offer the possibility of more efficient leukemia cell killing without the toxicity of intensive chemotherapy," said Dr. Jurcic.  "We are now studying this modality in combination with low-dose chemotherapy in older AML patients for whom new treatments are desperately needed.   The average age for AML patients is 68.  Most of these patients cannot tolerate intensive treatments, and their prognosis is extremely poor.  A drug like Actimab-A™ could allow them to avoid the side effects of standard chemotherapy."

Dr. Jurcic's presentation will focus on Actinium Pharmaceuticals' drug candidates Actimab-A™ and Bismab.  It will take place during the 8th Targeted Alpha Therapy (TAT) international symposium that will be held in Oak Ridge, TN.

About Actimab-A™

Actimab-A™ is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A™ consists of the Lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first co-developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site or Contact:

Segio Traversa , CEO
Actinium Pharmaceuticals, Inc.

Dennis S. Dobson Jr. , 203-258-0159
Tel:  (203) 258-0150

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
2. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
3. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
4. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
5. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
6. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
7. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
10. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
11. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
Post Your Comments:
(Date:11/30/2015)... 30, 2015   VolitionRx Limited (NYSE MKT: VNRX), ... for a broad range of cancer types and other conditions, ... Conference, which will be held December 1 - 3 in in ... will be David Kratochvil , Chief Financial Officer and ... Relations. ® blood-based tests for colorectal cancer ...
(Date:11/30/2015)... LONDON , November 30, 2015 Mexico ... Healthcare and Life Sciences Report 2015 . --> Pharmaboardroom ... 2015 . Latin America , a country ... , a country of over 122 million people. --> ... in healthcare, pharmaceuticals, or life sciences insights into the second largest ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Progressive Dental ... on January 29 and 30, 2016. The course welcomes dental professionals and members ... to learn how to better succeed in the modern dental marketplace. The course ...
(Date:11/30/2015)... ... , ... A record crowd gathered at the Pennsylvania Biotech Center of Bucks ... Blumberg Institute. , The institute, which is the research arm of the Hepatitis B ... the conference, which focused on ways companies can work to reduce the cost and ...
(Date:11/30/2015)... ... 30, 2015 , ... HemoTreat™ has announced that the company ... to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s Chief ... comparison chart and ingredient list allows our customers to quickly see why, and ...
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad ... looking to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the ... better night’s sleep. ChiliPad precisely regulates the surface temperature of each side of ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare ... centered orthopedic care. Led by John Vitolo, M.D., the center offers their ... the team at Advocare Orthopedic & Sports Medicine is ready to help their ...
Breaking Medicine News(10 mins):